NVO
Held by
0
portfolios on TandT
Bookmarked by
0
users
Platform exposure
—
13F filers
2
institutions
Market cap
$209.9B
4,427M shares
52-week range
$35.12 – $71.80
31% from low
Exchange
NYSE
ADRC
Borrow rate
0.32%
Easy to borrow
Price (6 mo)
Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
www.novonordisk.com- Employees
- 69,500
- IPO / List date
- Apr 30, 1981
Held by traders on TradeandTell
No one on the platform currently holds NVO.
Super investors & insiders
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 2,881,996 | $159.9M |
| Bridgewater Associatesas of 2025-09-30 | 138,947 | $7.7M |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Dividend history
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-30 | $1.2174 | 2026-04-08 |
| 2025-08-18 | $0.5843 | 2025-08-26 |
| 2025-03-31 | $1.1426 | 2025-04-08 |
| 2024-08-16 | $0.5169 | 2024-08-26 |
| 2024-03-22 | $0.9293 | 2024-04-02 |
| 2023-08-18 | $0.8763 | 2023-08-29 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-20 | 2-for-1 |
| 2014-01-09 | 5-for-1 |
| 2007-12-17 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded NVO yet.
$NVO chatter on StockTwits
$NVO The rise in the USD/DKK is essentially subtracted from the price in NOVO_B so it weighs down on the NVO price to keep the two 1:1. But it helps their fundamentals. The 10% drop in the dollar after Trump took office hurt Novo’s revenue quite a lot, so from that perspective a higher dollar is good and the past three months it has gone up 2,5%.
View on StockTwits ↗
$NVO people are just waking up. oh, did you say nvo was going to blow the doors off with oral weight loss? don’t wait so long your wife will say she married a dum mass.
View on StockTwits ↗
$NVO with the ma 200 and 200 ema crossing on the 15m, we might see a brief touch and then a bounce back up.
View on StockTwits ↗
$VKTX Did Viking just beat $NVO on start of Amylin??? Hey Doustar, we will take $38B…You need us more than we need you 👌
View on StockTwits ↗
$LLY $NVO $VKTX thanks Mike. You’ll be tell me Saturday comes after Friday next. Can you teach us how to count from 1-5 whilst we cover the obvious. Such a moronic post. blocked
View on StockTwits ↗
@Yass93 EU is still around +1%... thats good enough. I think EU is afraid of pullback on US... but the stock is still a great deal at this price so... go $NVO
View on StockTwits ↗
$NVO Whelp euro gave it the good ole college try then let it flop. Hopefully there is a better outcome once the US market opens.
View on StockTwits ↗
$VKTX $NVO $LLY The obesity drug market is currently dominated by Danish drugmaker Novo Nordisk and its American rival Eli Lilly and Co.
View on StockTwits ↗
$NVO big resistance coming up tomorrow. Clearing that is the road to $50, a rejection here could send it back down to $45, good luck.
View on StockTwits ↗
$NVO estimate 14/65 million seniors with Medicare will be eligible getting coverage for the first time in history on obesity treatment. Even if intial ramp up is 1 million population split between Lily and nvo. This will be insane
View on StockTwits ↗$NVO July 1 st. After two weeks the 300k to 500k population sign up initially for the obesity coverage will send this stock through $75
View on StockTwits ↗
$VKTX $AZN $NVO .....Just punching in a few phrase's on Gemini(free site though)....tonight they have 'offered' up AZN as a good fit for some or all of VKTX.....a chunk off the old VKTX seems more plausible at this stage though...anyways...just picking 'its' database for tidbits/crumbs...glta "The "Fixed-Dose Combo" Obsession: At the 2026 ADA meeting, AstraZeneca's R&D leadership explicitly stated their goal is to combine their oral GLP-1 (elecoglipron) with other mechanisms to maximize muscle-sparing weight loss. By acquiring Viking's amylin pipeline, AZN could build powerful, proprietary internal combinations (GLP-1 + GIP + Amylin) that mimic Novo Nordisk's high-potency CagriSema strategy."
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.